BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9766801)

  • 1. Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma.
    Yau JC; Germond C; Gluck S; Cripps C; Verma S; Burns BF; Koski TM; Lister DC; Goss GD
    Am J Hematol; 1998 Oct; 59(2):156-60. PubMed ID: 9766801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
    Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):20-3. PubMed ID: 2259919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone.
    Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R; van de Loo J
    Eur J Cancer; 1991; 27 Suppl 4():S37-9. PubMed ID: 1799474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
    Tirelli U; Errante D; Spina M; Gastaldi R; Nigra E; Nosari AM; Magnani G; Vaccher E
    Cancer; 1996 May; 77(10):2127-31. PubMed ID: 8640681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.
    Tirelli U; Errante D; Van Glabbeke M; Teodorovic I; Kluin-Nelemans JC; Thomas J; Bron D; Rosti G; Somers R; Zagonel V; Noordijk EM
    J Clin Oncol; 1998 Jan; 16(1):27-34. PubMed ID: 9440719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
    Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):32-5. PubMed ID: 8073307
    [No Abstract]   [Full Text] [Related]  

  • 8. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
    Tirelli U; Zagonel V; Errante D; Serraino D; Talamini R; De Cicco M; Carbone A; Monfardini S
    J Clin Oncol; 1992 Feb; 10(2):228-36. PubMed ID: 1732423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
    J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
    Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
    Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
    Chisesi T
    Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients.
    Tirelli U; Zagonel V; Sorio R; Errante D; Talamini R; Carbone A; Monfardini S
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):13-22. PubMed ID: 8073302
    [No Abstract]   [Full Text] [Related]  

  • 13. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
    Gregory SA; Vose J; Modiano M; Kraemer K; Rifkin R; Rubin A; Menduni T; Ghalie R
    Leuk Lymphoma; 2001 Jan; 40(3-4):315-24. PubMed ID: 11426553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of aggressive non-Hodgkin's lymphoma in aged patients with a combination of methyl-GAG, etoposide and prednimustine].
    Solal-Celigny P; Tertian G; Herrera A; Brousse N; Peuchmaur M
    Bull Cancer; 1990; 77(5):449-52. PubMed ID: 2400814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).
    Lichtman SM; Kolitz J; Budman DR; Schulman P; Vinciguerra V; Hoffman M; Mittelman A; Allen SL; Fusco D; Hayes FA
    Am J Clin Oncol; 2001 Aug; 24(4):360-2. PubMed ID: 11474261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Merli F; Federico M; Avanzini P; Ilariucci F; Stelitano C; Iannitto E; Colombi M; Vallisa D; Santagati G; Picinini L
    Haematologica; 1998 Mar; 83(3):217-21. PubMed ID: 9573675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).
    Santini G; Contu A; Porcellini A; Chisesi T; Coser P; Congiu AM; Morandi S; Manna A; Schintu GM; Quaini R
    Haematologica; 1991; 76(6):485-90. PubMed ID: 1820985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
    Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Fountzilas G; Papageorgiou E; Kiamouris C; Mantzios G; Anagnostopoulos A; Nicolaides C; Economopoulos T;
    Leuk Lymphoma; 2002 Jan; 43(1):111-4. PubMed ID: 11908713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.